Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.070
-0.145 (-4.50%)
Aug 4, 2025, 11:19 AM - Market open
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
$1,291,364
Profits / Employee
-$1,834,152
Market Cap
4.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -2 | -50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XBIO News
- 5 days ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 12 days ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 27 days ago - Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - Accesswire